Image: ceoworld.biz |
Nothing surprises me anymore about GlaxoSmithKline. It would appear that the World's second largest pharmaceutical company have found themselves [once again] under investigation from the authorities - this time in Finland.
According to Nelonen (Channel 4) news, the Chancellor of Justice is investigating if bribery was used in narcolepsy-suspect Pandemrix vaccine trade.
The Nelonen (Channel 4) news reports that the the investigation has begun because two individuals have reported their suspicions to the Chancellor. Investigation targets the Ministry of Health and THL, National Instute for Health and Welfare. THL has received more than six million euros last year from GlaxoSmithKline, which manufactures Pandemrix. THL has also had a key role in the decision to order Pandemrix to every Finnish inhabitant. [Source]
The investigation is also being reported on HELSINGIN SANOMAT, a popular Finnish journal.
HELSINGIN SANOMAT are also reporting that H1N1 vaccinations have been suspended over narcolepsy scare, at least 15 cases of narcolepsy among children and young people in past six months.
In separate, but related news, Sweden's Medical Products Agency have opened an inquiry into vaccinations for swine flu made by British pharmaceutical company GlaxoSmithKline, suspected of provoking narcolepsy.
The reports concern children aged between 12-16 years who developed symptoms compatible with narcolepsy, a chronic sleeping disorder, that occurred one to two months after vaccination against the H1N1 pandemic.
Narcolepsy is a neurological sleep disorder. It is not caused by mental illness or psychological problems. It is most likely affected by a number of genetic abnormalities that affect specific biologic factors in the brain, combined with a set off from environment, such as a virus. [Source]
What is it with GlaxoSmithKline and children?
Hat Tip: "Rams"
Fid
ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman
SIGNED COPIES HERE OR UNSIGNED FROM CHIPMUNKA PUBLISHING
No comments: